Amylin Pharmaceuticals Announces Online Summit

Company's First Online Summit to Provide Perspectives on Diabetes and Information From Topics Covered at the ADA's 70th Annual Scientific Sessions

Jun 07, 2010, 16:15 ET from Amylin Pharmaceuticals, Inc.

SAN DIEGO, June 7, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is hosting an online summit focusing on perspectives within the diabetes community and information from topics that will be discussed at the American Diabetes Association's (ADA's) upcoming 70th Annual Scientific Sessions in Orlando, FL.

Through the Online Summit, Amylin will digitally aggregate perspectives from leaders throughout the diabetes community, providing a resource to help advance understanding of the key issues facing the field, and viewpoints on the latest innovations and treatment strategies that will shape the future of diabetes care. Amylin is hosting the Online Summit in the weeks leading up to, and throughout the duration of, the ADA's Scientific Sessions. Additional "wrap-up" perspectives will be posted in the weeks following the conference.

Online perspectives will be updated multiple times per week with fresh content from myriad contributors, spanning roles in clinical care, research, health policy, patient advocacy and other interests. Content from the Online Summit will be made available, and archived for approximately 90 days, on Amylin's corporate Web site at www.amylin.com.  

The first entry, posted today, is an introduction to the Online Summit by David Maggs, MD, vice president, R&D Strategic Relations at Amylin Pharmaceuticals.  Additional entries will be posted regularly throughout the next two months.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.



RELATED LINKS

http://www.amylin.com